Physician profile
Daniel J Haas
NPI 1821005174
$4,962.96
in general payments reported to CMS, 2019-2025
24 companies · $693 in 2025
The $693 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $241 · 2021: $855 · 2022: $895 · 2023: $902 · 2024: $649 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129 · Entertainment: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,129.32 |
| Entertainment | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,341.27 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $636.21 | 2019-2021 | |
| Sight Sciences, INC. | $356.59 | 2020-2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $293.01 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $281.97 | 2022-2023 | Infuse |
| Horizon Therapeutics Plc | $240.00 | 2023 | Tepezza |
| Optos, INC. | $211.00 | 2022-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $191.81 | 2023-2024 | Myday Contact Lens |
| Allergan, INC. | $158.73 | 2019-2022 | |
| Dompe US, INC. | $135.79 | 2019-2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $135.58 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $131.55 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $121.87 | 2023 | Acthar |
| Amgen INC. | $118.52 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $111.72 | 2025 | Syfovre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $102.74 | 2024 | |
| Shire North American Group INC | $97.72 | 2019 | |
| Abbvie INC. | $64.50 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $57.58 | 2021 | |
| Quidel Corporation | $48.27 | 2019 | |
| Ani Pharmaceuticals, INC. | $46.18 | 2022 | |
| Biotissue Holdings INC. | $35.96 | 2021-2022 | |
| Coherus Oncology, INC. | $27.91 | 2022 | |
| Kala Pharmaceuticals, INC. | $16.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.